Komatsu Katsuya, Honmou Osamu, Suzuki Junpei, Houkin Kiyohiro, Hamada Hirofumi, Kocsis Jeffery D
Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido 060-8543, Japan.
Brain Res. 2010 Jun 2;1334:84-92. doi: 10.1016/j.brainres.2010.04.006. Epub 2010 Apr 9.
Intravenous transplantation of mesenchymal stem cells (MSCs) prepared from bone marrow ameliorates functional deficits in rat cerebral infarction models. Although several hypotheses to account for these therapeutic effects have been suggested, angiogenesis is thought to be largely responsible. MSCs were intravenously infused into rats in the relatively later time points after permanent middle cerebral artery occlusion (MCAO) to determine if they could contribute to neovascularization and functional recovery. Although MRI analysis revealed that only rats receiving MSCs 7days after MCAO exhibited decreased ischemic lesion volume than the control group, all MSCs treated rats receiving MSCs up to 1month after MCAO had greater angiogenesis near the border of the ischemic lesions and showed greater functional recovery in the treadmill stress test than did control rats. Thus, these results suggest that the time window of MSC therapy is at least over 1 month after cerebral infarction in the rat permanent MCAO model, and systemic delivery of MSCs in the later phase after cerebral ischemia may have beneficial effect through an angiogenic mechanism.
静脉注射由骨髓制备的间充质干细胞（MSCs）可改善大鼠脑梗死模型中的功能缺陷。尽管已经提出了几种解释这些治疗效果的假说，但血管生成被认为在很大程度上起了作用。在永久性大脑中动脉闭塞（MCAO）后的相对较晚时间点，将MSCs静脉注射到大鼠体内，以确定它们是否有助于新血管形成和功能恢复。尽管MRI分析显示，仅在MCAO后7天接受MSCs的大鼠与对照组相比，缺血性病变体积减小，但所有在MCAO后长达1个月接受MSCs治疗的大鼠，在缺血性病变边界附近有更多的血管生成，并且在跑步机应激试验中显示出比对照大鼠更好的功能恢复。因此，这些结果表明，在大鼠永久性MCAO模型中，MSC治疗的时间窗至少在脑梗死1个月以上，脑缺血后期全身递送MSCs可能通过血管生成机制产生有益作用。
